Nichi-Iko Delays US Infliximab Amid Coronavirus Outbreak

As Japanese Company Trains Focus On Bevacizumab

 
• By Dean Rudge
Delayed
Nichi-Iko's ambitions for the US infliximab market have been pushed back • Source: Shutterstock

More from Strategy

More from Business